Endovia Health Sciences, Inc. — Form 8-K
Filed September 24, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
Endovia Health Sciences issued a secured convertible promissory note for $510,000 principal (with $576,271 original issue discount amount) to C/M Capital Master Fund, LP on September 18, 2026. The note converts at $1.75/share (or $0.01 above closing price, whichever is lower), matures in 12 months, bears 7% interest on default, and is secured by all company assets with priority over all existing/future debt except related-party obligations ranking pari passu. The investment supports commercialization of a licensed product under an exclusive license agreement with Argent Biopharma Limited dated July 2, 2026.
Why this rating
Major dilutive financing for $6.5M company; 30% of proceeds must repay note; extensive investor protections and conversion rights; governance restrictions; conversion could substantially dilute equity.
Tradability signal
NO TRADE
No trade: price $0.19 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.19 ▲ 0.00% | at our read · unknown $0.19 | +10 min · unknown $0.18 ▼ 3.80% | +30 min · unknown $0.18 ▼ 3.59% | +1 hr · unknown $0.19 ▼ 1.16% | +4 hrs · unknown $0.19 ▲ 2.16% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.